Inactive Instrument

Analyst Reco. Vical Incorporated Nasdaq

Equities

Oppenheimer Adjusts Fresh Tracks Therapeutics Price Target to $4 From $9, Maintains Outperform Rating	22-11-14	MT
Oppenheimer Adjusts Price Target on Fresh Tracks Therapeutics to $9 From $1, Maintains Outperform Rating	22-09-27	MT
HC Wainwright Adjusts Brickell Biotech's Price Target to $4.50 From $2, Keeps Buy Rating	22-08-16	MT
Lake Street Downgrades Brickell Biotech to Hold From Buy, Lowers Price Target to $0.25 From $2	22-05-13	MT
Oppenheimer Adjusts Brickell Biotech's Price Target to $1 From $4, Maintains Outperform Rating	22-05-13	MT
Wall Street Set for Higher Open Ahead of Fed Funds Rate Announcement, ISM's Services Index	22-05-04	MT
William Blair Initiates Coverage on Brickell Biotech With Outperform Rating	22-03-08	MT
HC Wainwright Starts Brickell Biotech at Buy With $2 Price Target	22-01-18	MT

No results for this search